Visit Us at Booth #512 | February 9–12, 2026 | San Diego Convention Center | San Diego, CA
Join Bio-Techne at Advanced Therapies Week
Discover next-generation tools designed to overcome key challenges in cell therapy manufacturing. Learn how Bio-Techne is driving innovation in cell therapy manufacturing with closed systems, AI-engineered proteins and automated cell assays, enabling faster scalability, greater commercial readiness and better patient outcomes.
Featured Presentations
Next Gen Tools for Cell Therapy Manufacturing: Addressing Key Reagent Challenges
Speaker: David Hermanson, Ph.D., Director of Cell Therapy Solutions, Bio-Techne
Time/Location: Wednesday, February 11 / 2:00–2:15 PM, Theatre 1
Session Highlights: Cell therapy manufacturing remains a bottleneck for commercial success due to process complexity and excessive hands-on time. Bio-Techne is addressing these critical challenges in cell therapy manufacturing
- ProPak™ closed system GMP cytokine delivery – Eliminates reconstitution and aliquoting, reducing risk and hands-on time
- AI-engineered heat-stable cytokines - Reduce cold-chain logistics and enhance cell expansion
- Ella automated ELISA platform – Rapid and simple cytokine release assays
These innovations streamline processes, reduce cost and complexity, and improve scalability and regulatory confidence.
Poster Presentation
Title: Enhancing Efficiency and Safety in T Cell Therapy Manufacturing with Closed System Ready-to-Use Liquid GMP Cytokines
Presenter: Jessica Fiege, R&D Supervisor
Abstract: Closed system immunotherapy manufacturing workflows minimize manual touchpoints and dedicated cleanroom time, as well as reduce the risk of error and contamination. One manufacturing bottleneck is the open, manual delivery of cytokines, which can be labor-intensive, requiring reconstitution and aliquoting in a biological safety cabinet. To minimize contamination and simplify the workflow, we packaged ready-to-use liquid GMP cytokines in single-use ProPak™ bags with weldable tubing for easy integration into closed system workflows. This innovative approach allows for optimal dosing of GMP cytokines without the need for manual manipulation or cytokine spiking in a biosafety cabinet, enhancing both scalability and safety in T cell therapy production. Here we demonstrate that IL-2, IL-7 and IL-15 GMP cytokines packaged into ProPaks can be recovered into media bags and maintain bioactivity. Additionally, ProPak GMP cytokines support T cell growth and maintain T cell viability equivalently to lyophilized cytokine formats. The implementation of ready-to-use liquid GMP cytokines in single-use bags with weldable tubing enhances manufacturability and safety in T cell therapy production.
Time/Location: Tuesday, February 10 / 3:45–4:54 PM
Wednesday, February 11 / 3:00–4:00 PM
Connect with Us
Visit our booth to explore:
- ProPak™ GMP cytokine solutions
- AI-engineered proteins for next-gen manufacturing
- End-to-end tools for cell and gene therapy workflows
What's New in Cell Therapy
Optimize Cytokine Delivery for Scalable T Cell Manufacturing
Optimize Cytokine Delivery for Scalable T Cell Manufacturing
Reduce variability and risk in your T cell therapy with ProPak™ GMP IL-7 and IL-15 in single-use bags with weldable tubing. ProPak™ Cytokines are designed for easy integration into closed process workflows with no reconstitution or aliquoting required.
Grow Robust T Cell Cultures for the Clinic
Grow Robust T Cell Cultures for the Clinic
Designed to integrate seamlessly into your pre-clinical or clinical T cell therapy, this GMP T cell media formulation has been adopted by both academic and biopharma clinical programs, mitigating risk associated with IND submissions.
AI Modified Proteins Driving Cell Therapy Innovation
AI Modified Proteins Driving Cell Therapy Innovation
AI-modified proteins deliver superior stability, functionality, and consistency compared to conventional proteins, accelerating therapeutic development.
Quantify IFN-gamma with Confidence
Quantify IFN-gamma with Confidence
Accelerate QC release with Simple Plex™ immunoassays on the Ella™ automated benchtop ELISA platform. Compliant with 21 CFR Part 11, Ella is the ideal solution for GMP environments. Gain critical insights in just 90 minutes, with pg-level sensitivity and the reproducibility needed to ensure regulatory compliance.
Flex and Fine-Tune T Cell Activation and Expansion
Flex and Fine-Tune T Cell Activation and Expansion
Advance your immune cell therapy program into clinical manufacturing with GMP antibodies for ex vivo use. Our Recombinant Human CD3 GMP Antibody and Human CD28 GMP Antibody are adaptable to your platform and allow you the flexibility to fine-tune your T cell activation and expansion.
Simplify Your Transition to the Clinic
Simplify Your Transition to the Clinic
Transitioning your cell therapy program from bench to clinic can be a complex and frustrating process. We have vast experience helping customers to bring their novel cell therapies to clinical trials. Learn how Bio-Techne makes your transition to GMP as seamless as possible.
Application Notes
- Quantify Secreted T Cell Activation Markers
- Lentiviral Vector Analysis for Cell and Gene Therapy Made Simple
- G-Rex® Fill-and-Forget T Cell Manufacturing Workflow: Touch-free T Cell Expansion
- Analytical Tools to Evaluate CAR-T Cell Signaling & Activation
- Driving CAR-T Therapy to Market in the Fast Lane
- Automation Advancements in Immune Cell Therapy Workflow: IFN-gamma QC Release Testing
- Fast and Reproducible Adeno-Associated Virus Vector Titration with Simple Plex Assays on Ella
- Generation and Characterization of iPSC-derived Insulin-producing Pancreatic Beta Islets
Webinars
- Streamlining Immune Cell Therapy Manufacturing Workflows with Process-Sized Cytokine Vials
- Protein Analytics Strategies for Gene Therapy - From Viral Vector Characterization to Clinical Trials
- Automated Immunoassay Platforms for Enhancing AAV Research
Blogs
- Consistency is Critical: Standardization and Quality Control Frameworks for Immune Cell Therapy Development
- GMP Raw Materials: Meeting the Demand for Cell Therapy
- 3 Steps Toward Cell and Gene Therapy Commercialization
- Strengthening Your CAR Toolkit: Analyzing CAR Expression During CAR-T and NK Cell Therapy Development
- Developing Innovative CAR T Cell Therapies to Treat Solid Tumors
| GMP Proteins - Futureproof your cell therapy manufacturing with our GMP cytokines and growth factors. | Request Sample |
| GMP Antibodies - Add flexibility to your immune cell therapy manufacturing workflow with GMP antibodies for T cell activation. | Request Sample |